Global Opioid-Induced Constipation Market 2015-2019

オピオイド誘発性便秘治療薬の世界市場2015-2019

◆タイトル:Global Opioid-Induced Constipation Market 2015-2019
◆商品コード:IRTNTR6305
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年7月1日
◆ページ数:69
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、オピオイド誘発性便秘治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、オピオイド誘発性便秘治療薬の世界市場規模及び予測、作用機序別分析、投与経路(ROA)別分析、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Opioid-induced Constipation
Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite. Opioid-induced constipation can be managed by changing lifestyle along with the use of targeted therapies and other OTC and off-label drugs.
Technavio’s analysts forecast the global opioid-induced constipation market to grow at a CAGR of 30.18% over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the global opioid-induced constipation market for 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of opioid-induced constipation, which includes branded drugs, off-label products, and OTC drugs.

On the basis of the mechanism of action of drugs, the market is grouped into the following categories:
• Peripherally Acting Mu-opioid Receptor Antagonist
• Locally Acting Chloride Channel Activator
• Others

On the basis of the route of administration of drugs, the market is grouped into the following categories:
• Oral
• Parenteral

On the basis of the dosage form of drugs, the market is grouped into the following categories:
• Solid
• Liquid

Technavio’s report, Global Opioid-induced Constipation Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• AstraZeneca
• Takeda Pharmaceutical
• Valeant Pharmaceuticals International

[Other Prominent Vendors]
• Abbott
• Bayer
• Boehringer Ingelheim
• C.B. Fleet
• Cosmo Pharmaceuticals
• Daewoong
• Daiichi Sankyo
• GlaxoSmithKline
• Ironwood Pharmaceuticals
• Johnson & Johnson
• Merck
• Mundipharma
• Nektar Therapeutics
• Pfizer
• Progenics Pharmaceuticals
• Shionogi
• SLA Pharma
• Sucampo
• Synergy Pharmaceuticals
• Theravance

[Market Driver]
• Unmet Medical Needs
• For a full, detailed list, view our report

[Market Challenge]
• Availability of OTC and Off-label Drugs
• For a full, detailed list, view our report

[Market Trend]
• Shift to Targeted Therapy
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Amitiza
04.1.2 Movantik/Moventig
04.1.3 Relistor

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disease Overview
07.1 Understanding Opioid-induced Constipation
07.2 Symptoms
07.3 Pathophysiology
07.4 Epidemiology
07.5 Diagnosis
07.5.1 Patient History
07.5.2 Bristol Stool Form Scale
07.5.3 Physical Examination
07.5.4 Laboratory Tests
07.5.5 Further Investigational Procedures
07.6 Treatment and Management
07.6.1 Pharmacotherapeutic Approach
07.6.2 Non-pharmacotherapeutic Approach

08.Pipeline Portfolio
08.1 Key Information of Pipeline Molecules
08.1.1 Naldemedine
08.1.2 Linaclotide
08.1.3 Axelopran/TD-1211
08.1.4 SP-333
08.1.5 Oral Naloxone

09.Market Landscape
09.1 Market Overview
09.2 Market Size and Forecast
09.3 Five Forces Analysis

10.Market Segmentation by Mechanism of Action
10.1 Peripherally Acting Mu-opioid Receptor Antagonist
10.2 Locally Acting Chloride Channel Activator
10.3 Others

11.Market Segmentation by Route of Administration
11.1 Oral
11.2 Parenteral

12.Market Segmentation by Dosage Form
12.1 Solid
12.2 Liquid

13.Geographical Segmentation

14.Buying Criteria

15.Market Growth Drivers

16.Drivers and their Impact

17.Market Challenges

18.Impact of Drivers and Challenges

19.Market Trends

20.Trends and their Impact

21.Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Takeda Pharmaceutical
21.2.2 Valeant Pharmaceuticals International
21.2.3 AstraZeneca
21.3 Other and Future Prominent Vendors

22.Key Vendor Analysis
22.1 AstraZeneca plc
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Business Segmentation by Revenue 2013
22.1.4 Business Segmentation by Revenue 2011-2013
22.1.5 Sales by Geography
22.1.6 Business Strategy
22.1.7 Key Developments
22.1.8 SWOT Analysis
22.2 Takeda Pharmaceuticals
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Business Segmentation by Revenue 2013
22.2.4 Business Segmentation by Revenue 2013
22.2.5 Geographical Segmentation by Revenue 2013
22.2.6 Business Strategy
22.2.7 Recent Developments
22.2.8 SWOT Analysis
22.3 Valeant Pharmaceuticals International
22.3.1 Key Facts
22.3.2 Business Overview
22.3.3 Business Segmentation by Revenue 2013
22.3.4 Business Segmentation by Revenue 2012 and 2013
22.3.5 Sales by Geography
22.3.6 Business Strategy
22.3.7 Key Developments
22.3.8 SWOT Analysis

23.Other Reports in this Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Pipeline Drugs: Opioid-induced Constipation
Exhibit 3: Snapshot of Global Opioid-induced Constipation Market
Exhibit 4: Global Opioid-induced Constipation Market 2014-2019 ($ millions)
Exhibit 5: Segmentation of Global Opioid-induced Constipation Market by Mechanism of Action
Exhibit 6: Segmentation of Global Opioid-induced Constipation Market by Route of Administration
Exhibit 7: Segmentation of Global Opioid-induced Constipation Market by Dosage Form
Exhibit 8: Segmentation of Global Opioid-induced Constipation Market by Geography 2014
Exhibit 9: Drivers of Global Opioid-induced Constipation Market
Exhibit 10: Challenges in the Global Opioid-induced Constipation Market
Exhibit 11: Trends of Global Opioid-induced Constipation Market
Exhibit 12: Takeda Pharmaceuticals: Key Takeaways
Exhibit 13: Valeant Pharmaceuticals International: Key Takeaways
Exhibit 14: AstraZeneca: Key Takeaways
Exhibit 15: AstraZeneca plc: Business Segmentation by Revenue 2013
Exhibit 16: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 17: AstraZeneca plc: Sales by Geography 2013
Exhibit 18: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013
Exhibit 19: Takeda Pharmaceuticals: Business Segmentation by Revenue 2013 (US$ million)
Exhibit 20: Takeda Pharmaceuticals: Geographical Segmentation by Revenue 2013
Exhibit 21: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2013
Exhibit 22: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 23: Valeant Pharmaceuticals International: Sales by Geography 2013



【掲載企業】

AstraZeneca, Takeda Pharmaceutical, Valeant Pharmaceuticals International, Abbott, Bayer, Boehringer Ingelheim, C.B. Fleet, Cosmo Pharmaceuticals, Daewoong, Daiichi Sankyo, GlaxoSmithKline, Ironwood Pharmaceuticals, Johnson & Johnson, Merck, Mundipharma, Nektar Therapeutics, Pfizer, Progenics Pharmaceuticals, Shionogi, SLA Pharma, Sucampo, Synergy Pharmaceuticals, Theravance

【資料のキーワード】

オピオイド誘発性便秘、オピオイド誘発性便秘治療薬、製薬、製品パイプライン、医薬品、オピオイド

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[オピオイド誘発性便秘治療薬の世界市場2015-2019] (Global Opioid-Induced Constipation Market 2015-2019 / IRTNTR6305)販売に関する免責事項
[オピオイド誘発性便秘治療薬の世界市場2015-2019] (Global Opioid-Induced Constipation Market 2015-2019 / IRTNTR6305)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆